サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1631384

子宮がん診断検査の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）

Uterine Cancer Diagnostic Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 241 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
子宮がん診断検査の世界市場：業界分析、規模、シェア、成長、動向、予測（2025年～2032年）
出版日: 2025年01月09日
発行: Persistence Market Research
ページ情報: 英文 241 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の子宮がん診断検査の市場規模は、2025年に35億4,710万米ドルになるとみられ、2025年～2032年の予測期間に9.60%のCAGRで拡大し、2032年には67億3,890万米ドルに達すると予測されています。

世界の子宮がん診断検査市場は、子宮内膜がんや子宮肉腫を含む子宮体がんの検出を目的とした超音波検査、生検法、血液検査などの診断ソリューションで構成されます。市場成長の原動力は、子宮体がんの有病率の増加、診断技術の進歩、高齢者人口の増加です。ヘルスケアインフラの改善、意識向上プログラム、政府の取り組みも市場拡大を支えています。

いくつかの要因が世界の子宮がん診断検査市場の成長を促進しています。特に閉経後や肥満の女性の間で子宮体がんの有病率が上昇していることが、早期発見法の需要を強調しています。経膣超音波スキャンやCA125腫瘍マーカー血液検査などの診断技術の進歩により、精度と信頼性が向上し、市場導入に拍車をかけています。特に新興経済諸国におけるヘルスケア支出の増加は、診断ソリューションの開発と利用しやすさを支えています。さらに、女性の健康とがん検診を推進する政府の取り組みと早期診断に対する意識の高まりが、市場の成長に大きく寄与しています。

子宮がん診断検査市場は、技術の進歩とヘルスケアアクセスの拡大により大きな成長機会を提供しています。低侵襲の診断ツールの開発は患者のコンプライアンスを高め、市場の普及を拡大します。新興国は、ヘルスケアインフラへの投資の増加やがん検診に対する政府の支援イニシアティブにより、未開拓の可能性を秘めています。診断ソリューション・プロバイダーとヘルスケア機関のパートナーシップは、イノベーションを加速し、サービス提供を拡大することができます。さらに、個別化医療と精密診断への注目の高まりは、市場拡大の新たな道を提供します。

当レポートでは、世界の子宮がん診断検査市場について調査し、がんタイプ別、診断検査タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 子宮がん診断検査市場の視点

第4章 世界の子宮がん診断検査市場- 主な調査内容

第5章 北米の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）

第6章 ラテンアメリカの子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）

第7章 欧州の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）

第8章 中国を除くアジア太平洋の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）

第9章 中国の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）

第10章 中東・アフリカの子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）

第11章 予測要因：関連性と影響

第12章 競合情勢

  • 競合ダッシュボード
  • 企業プロファイル（詳細- 概要、財務、戦略、最近の動向）
  • 主要人物
    • Abbott
    • Roche Holdings AG
    • Siemens AG
    • Danaher
    • BioMerieux SA

第13章 世界の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）、地域別

第14章 世界の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）、がんタイプ別

第15章 世界の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）、診断検査タイプ別

第16章 世界の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）、エンドユーザー別

第17章 世界の子宮がん診断検査市場分析（2019年～2024年）および予測（2025年～2032年）

第18章 使用される仮定と頭字語

第19章 調査手法

目次
Product Code: PMRREP17005

Persistence Market Research has recently released a comprehensive report on the global Uterine Cancer Diagnostic Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Uterine Cancer Diagnostic Testing Market Size (2025E): US$ 3,547.10 Mn
  • Projected Market Value (2032F): US$ 6,738.90 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 9.60%

Uterine Cancer Diagnostic Testing Market - Report Scope:

The global uterine cancer diagnostic testing market comprises diagnostic solutions such as ultrasound scanning, biopsy procedures, and blood tests aimed at detecting uterine cancer, which includes endometrial carcinoma and uterine sarcoma. The market growth is driven by the increasing prevalence of uterine cancer, advancements in diagnostic technologies, and the rising geriatric population. Improved healthcare infrastructure, awareness programs, and government initiatives also support market expansion.

Market Drivers:

Several factors are propelling the growth of the global uterine cancer diagnostic testing market. The rising prevalence of uterine cancer, particularly among post-menopausal and obese women, underscores the demand for early detection methods. Advances in diagnostic techniques, such as transvaginal ultrasound scanning and CA125 tumor marker blood tests, have improved accuracy and reliability, fueling market adoption. Increasing healthcare expenditure, especially in emerging economies, supports the development and accessibility of diagnostic solutions. Furthermore, government initiatives promoting women's health and cancer screenings, combined with rising awareness about early diagnosis, contribute significantly to market growth.

Market Restraints:

Despite the promising growth trajectory, the uterine cancer diagnostic testing market faces several challenges. High costs associated with advanced diagnostic procedures and limited healthcare infrastructure in certain regions can hinder market penetration. Awareness about uterine cancer diagnosis remains low in developing countries, impacting timely detection and treatment. The complexity and invasiveness of certain diagnostic procedures, such as dilation and curettage, may deter patients, particularly in regions with cultural and social barriers to medical intervention.

Market Opportunities:

The uterine cancer diagnostic testing market offers significant growth opportunities driven by technological advancements and expanding healthcare access. Development of minimally invasive diagnostic tools enhances patient compliance and broadens market adoption. Emerging economies present untapped potential due to increasing investments in healthcare infrastructure and government-backed initiatives for cancer screenings. Partnerships between diagnostic solution providers and healthcare organizations can accelerate innovation and expand service delivery. Additionally, the growing focus on personalized medicine and precision diagnostics provides new avenues for market expansion.

Key Questions Answered in the Report:

1. What are the primary factors driving the global growth of the uterine cancer diagnostic testing market?

2. Which diagnostic solutions are gaining the highest adoption across different regions?

3. How are advancements in diagnostic technologies shaping the competitive landscape of the uterine cancer diagnostic testing market?

4. Who are the key players in the uterine cancer diagnostic testing market, and what strategies are they employing to maintain their market positions?

5. What are the emerging trends and future outlooks for the global uterine cancer diagnostic testing market?

Competitive Intelligence and Business Strategy:

Leading companies in the global uterine cancer diagnostic testing market, such as Siemens Healthineers, Hologic, and GE Healthcare, are focusing on technological innovations and expanding their product portfolios to gain a competitive edge. These companies are leveraging collaborations with healthcare providers and research institutions to accelerate the development of advanced diagnostic solutions. Investments in AI-based imaging and non-invasive diagnostic technologies further support market growth. Additionally, companies are emphasizing affordability and accessibility to cater to diverse patient demographics, particularly in emerging economies.

Key Companies Profiled:

  • Abbott
  • Roche Holdings AG
  • Siemens AG
  • Danaher
  • BioMerieux SA
  • Others

Uterine Cancer Diagnostic Testing Market Segmentation:

By Cancer Type:

  • Endometrial Carcinoma
  • Uterine Sarcoma

By Diagnostic Test Type:

  • Ultrasound Scanning
  • Biopsy Procedures
  • Blood Tests

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cancer Research Institutes
  • Specialized Clinics
  • Diagnostic Laboratories

By Region:

  • North America
  • Europe
  • Latin America
  • South East Asia & Pacific
  • Middle East & Africa (MEA)
  • China
  • Japan

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations
  • 1.4. Wheel of Fortune

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. Uterine Cancer Diagnostic Testing Market View Point

  • 3.1. Macro-Economic Factors
  • 3.2. Market Drivers and Restraints
  • 3.3. Opportunity Analysis
  • 3.4. Global Key trends
  • 3.5. Reimbursement Scenario

4. Global Uterine Cancer Diagnostic Testing Market - Key Inclusions

  • 4.1. Regional Average Pricing Analysis
  • 4.2. Parent Market Assessment
  • 4.3. Epidemiology

5. North America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 5.1. Introduction
  • 5.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 5.2.1. U.S.
    • 5.2.2. Canada
  • 5.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 5.3.1. U.S.
    • 5.3.2. Canada
  • 5.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 5.4.1. Uterine Sarcoma
    • 5.4.2. Endometrial Carcinomas
  • 5.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 5.5.1. Uterine Sarcoma
    • 5.5.2. Endometrial Carcinomas
  • 5.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 5.6.1. Ultrasound Scanning
      • 5.6.1.1. Abdominal Ultrasound
      • 5.6.1.2. Transvaginal Ultrasound
    • 5.6.2. Biopsy
      • 5.6.2.1. Endometrial Biopsy
      • 5.6.2.2. Hysteroscopy
      • 5.6.2.3. Dilation and curettage
    • 5.6.3. Blood tests
      • 5.6.3.1. Complete blood Count
      • 5.6.3.2. CA-125 blood test
  • 5.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 5.7.1. Ultrasound Scanning
      • 5.7.1.1. Abdominal Ultrasound
      • 5.7.1.2. Transvaginal Ultrasound
    • 5.7.2. Biopsy
      • 5.7.2.1. Endometrial Biopsy
      • 5.7.2.2. Hysteroscopy
      • 5.7.2.3. Dilation and curettage
    • 5.7.3. Blood tests
      • 5.7.3.1. Complete blood Count
      • 5.7.3.2. CA-125 blood test
  • 5.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 5.8.1. Hospitals
    • 5.8.2. Ambulatory Surgical Centers
    • 5.8.3. Cancer Research Centers
    • 5.8.4. Specialized Clinics
    • 5.8.5. Diagnostic Laboratories
    • 5.8.6. Others
  • 5.9. Market Size Analysis 2025 - 2032, By End User
    • 5.9.1. Hospitals
    • 5.9.2. Ambulatory Surgical Centers
    • 5.9.3. Cancer Research Centers
    • 5.9.4. Specialized Clinics
    • 5.9.5. Diagnostic Laboratories
    • 5.9.6. Others
  • 5.10. Drivers and Restraints: Impact Analysis
  • 5.11. Market Attractiveness Analysis
    • 5.11.1. By Cancer Type
    • 5.11.2. By Test Type
    • 5.11.3. By End user
    • 5.11.4. By Country

6. Latin America Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 6.1. Introduction
  • 6.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 6.2.1. Brazil
    • 6.2.2. Mexico
    • 6.2.3. Rest of Latin America
  • 6.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 6.3.1. Brazil
    • 6.3.2. Mexico
    • 6.3.3. Rest of Latin America
  • 6.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 6.4.1. Uterine Sarcoma
    • 6.4.2. Endometrial Carcinomas
  • 6.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 6.5.1. Uterine Sarcoma
    • 6.5.2. Endometrial Carcinomas
  • 6.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 6.6.1. Ultrasound Scanning
      • 6.6.1.1. Abdominal Ultrasound
      • 6.6.1.2. Transvaginal Ultrasound
    • 6.6.2. Biopsy
      • 6.6.2.1. Endometrial Biopsy
      • 6.6.2.2. Hysteroscopy
      • 6.6.2.3. Dilation and curettage
    • 6.6.3. Blood tests
      • 6.6.3.1. Complete blood Count
      • 6.6.3.2. CA-125 blood test
  • 6.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 6.7.1. Ultrasound Scanning
      • 6.7.1.1. Abdominal Ultrasound
      • 6.7.1.2. Transvaginal Ultrasound
    • 6.7.2. Biopsy
      • 6.7.2.1. Endometrial Biopsy
      • 6.7.2.2. Hysteroscopy
      • 6.7.2.3. Dilation and curettage
    • 6.7.3. Blood tests
      • 6.7.3.1. Complete blood Count
      • 6.7.3.2. CA-125 blood test
  • 6.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 6.8.1. Hospitals
    • 6.8.2. Ambulatory Surgical Centers
    • 6.8.3. Cancer Research Centers
    • 6.8.4. Specialized Clinics
    • 6.8.5. Diagnostic Laboratories
    • 6.8.6. Others
  • 6.9. Market Size Analysis 2025 - 2032, By End User
    • 6.9.1. Hospitals
    • 6.9.2. Ambulatory Surgical Centers
    • 6.9.3. Cancer Research Centers
    • 6.9.4. Specialized Clinics
    • 6.9.5. Diagnostic Laboratories
    • 6.9.6. Others
  • 6.10. Drivers and Restraints: Impact Analysis
  • 6.11. Market Attractiveness Analysis
    • 6.11.1. By Cancer Type
    • 6.11.2. By Test Type
    • 6.11.3. By End user
    • 6.11.4. By Country

7. Europe Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 7.1. Introduction
  • 7.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 7.2.1. Germany
    • 7.2.2. U.K.
    • 7.2.3. France
    • 7.2.4. Italy
    • 7.2.5. Spain
    • 7.2.6. Poland
    • 7.2.7. Russia
    • 7.2.8. Rest of Europe
  • 7.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Poland
    • 7.3.7. Russia
    • 7.3.8. Rest of Europe
  • 7.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 7.4.1. Uterine Sarcoma
    • 7.4.2. Endometrial Carcinomas
  • 7.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 7.5.1. Uterine Sarcoma
    • 7.5.2. Endometrial Carcinomas
  • 7.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 7.6.1. Ultrasound Scanning
      • 7.6.1.1. Abdominal Ultrasound
      • 7.6.1.2. Transvaginal Ultrasound
    • 7.6.2. Biopsy
      • 7.6.2.1. Endometrial Biopsy
      • 7.6.2.2. Hysteroscopy
      • 7.6.2.3. Dilation and curettage
    • 7.6.3. Blood tests
      • 7.6.3.1. Complete blood Count
      • 7.6.3.2. CA-125 blood test
  • 7.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 7.7.1. Ultrasound Scanning
      • 7.7.1.1. Abdominal Ultrasound
      • 7.7.1.2. Transvaginal Ultrasound
    • 7.7.2. Biopsy
      • 7.7.2.1. Endometrial Biopsy
      • 7.7.2.2. Hysteroscopy
      • 7.7.2.3. Dilation and curettage
    • 7.7.3. Blood tests
      • 7.7.3.1. Complete blood Count
      • 7.7.3.2. CA-125 blood test
  • 7.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 7.8.1. Hospitals
    • 7.8.2. Ambulatory Surgical Centers
    • 7.8.3. Cancer Research Centers
    • 7.8.4. Specialized Clinics
    • 7.8.5. Diagnostic Laboratories
    • 7.8.6. Others
  • 7.9. Market Size Analysis 2025 - 2032, By End User
    • 7.9.1. Hospitals
    • 7.9.2. Ambulatory Surgical Centers
    • 7.9.3. Cancer Research Centers
    • 7.9.4. Specialized Clinics
    • 7.9.5. Diagnostic Laboratories
    • 7.9.6. Others
  • 7.10. Drivers and Restraints: Impact Analysis
  • 7.11. Market Attractiveness Analysis
    • 7.11.1. By Cancer Type
    • 7.11.2. By Test Type
    • 7.11.3. By End user
    • 7.11.4. By Country

8. Asia Pacific Excluding China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 8.1. Introduction
  • 8.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. Australia and New Zealand
    • 8.2.5. Rest of APAC
  • 8.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 8.3.1. China
    • 8.3.2. India
    • 8.3.3. Japan
    • 8.3.4. Australia and New Zealand
    • 8.3.5. Rest of APAC
  • 8.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 8.4.1. Uterine Sarcoma
    • 8.4.2. Endometrial Carcinomas
  • 8.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 8.5.1. Uterine Sarcoma
    • 8.5.2. Endometrial Carcinomas
  • 8.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 8.6.1. Ultrasound Scanning
      • 8.6.1.1. Abdominal Ultrasound
      • 8.6.1.2. Transvaginal Ultrasound
    • 8.6.2. Biopsy
      • 8.6.2.1. Endometrial Biopsy
      • 8.6.2.2. Hysteroscopy
      • 8.6.2.3. Dilation and curettage
    • 8.6.3. Blood tests
      • 8.6.3.1. Complete blood Count
      • 8.6.3.2. CA-125 blood test
  • 8.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 8.7.1. Ultrasound Scanning
      • 8.7.1.1. Abdominal Ultrasound
      • 8.7.1.2. Transvaginal Ultrasound
    • 8.7.2. Biopsy
      • 8.7.2.1. Endometrial Biopsy
      • 8.7.2.2. Hysteroscopy
      • 8.7.2.3. Dilation and curettage
    • 8.7.3. Blood tests
      • 8.7.3.1. Complete blood Count
      • 8.7.3.2. CA-125 blood test
  • 8.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 8.8.1. Hospitals
    • 8.8.2. Ambulatory Surgical Centers
    • 8.8.3. Cancer Research Centers
    • 8.8.4. Specialized Clinics
    • 8.8.5. Diagnostic Laboratories
    • 8.8.6. Others
  • 8.9. Market Size Analysis 2025 - 2032, By End User
    • 8.9.1. Hospitals
    • 8.9.2. Ambulatory Surgical Centers
    • 8.9.3. Cancer Research Centers
    • 8.9.4. Specialized Clinics
    • 8.9.5. Diagnostic Laboratories
    • 8.9.6. Others
  • 8.10. Drivers and Restraints: Impact Analysis
  • 8.11. Market Attractiveness Analysis
    • 8.11.1. By Cancer Type
    • 8.11.2. By Test Type
    • 8.11.3. By End user
    • 8.11.4. By Country

9. China Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 9.1. Introduction
  • 9.2. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 9.2.1. Uterine Sarcoma
    • 9.2.2. Endometrial Carcinomas
  • 9.3. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 9.3.1. Uterine Sarcoma
    • 9.3.2. Endometrial Carcinomas
  • 9.4. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 9.4.1. Ultrasound Scanning
      • 9.4.1.1. Abdominal Ultrasound
      • 9.4.1.2. Transvaginal Ultrasound
    • 9.4.2. Biopsy
      • 9.4.2.1. Endometrial Biopsy
      • 9.4.2.2. Hysteroscopy
      • 9.4.2.3. Dilation and curettage
    • 9.4.3. Blood tests
      • 9.4.3.1. Complete blood Count
      • 9.4.3.2. CA-125 blood test
  • 9.5. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 9.5.1. Ultrasound Scanning
      • 9.5.1.1. Abdominal Ultrasound
      • 9.5.1.2. Transvaginal Ultrasound
    • 9.5.2. Biopsy
      • 9.5.2.1. Endometrial Biopsy
      • 9.5.2.2. Hysteroscopy
      • 9.5.2.3. Dilation and curettage
    • 9.5.3. Blood tests
      • 9.5.3.1. Complete blood Count
      • 9.5.3.2. CA-125 blood test
  • 9.6. Historical Market Size Analysis 2019 - 2024, By End User
    • 9.6.1. Hospitals
    • 9.6.2. Ambulatory Surgical Centers
    • 9.6.3. Cancer Research Centers
    • 9.6.4. Specialized Clinics
    • 9.6.5. Diagnostic Laboratories
    • 9.6.6. Others
  • 9.7. Market Size Analysis 2025 - 2032, By End User
    • 9.7.1. Hospitals
    • 9.7.2. Ambulatory Surgical Centers
    • 9.7.3. Cancer Research Centers
    • 9.7.4. Specialized Clinics
    • 9.7.5. Diagnostic Laboratories
    • 9.7.6. Others
  • 9.8. Drivers and Restraints: Impact Analysis
  • 9.9. Market Attractiveness Analysis
    • 9.9.1. By Cancer Type
    • 9.9.2. By Test Type
    • 9.9.3. By End user
    • 9.9.4. By Country

10. Middle East and Africa (MEA) Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) By Country, 2019 - 2024
    • 10.2.1. South Africa
    • 10.2.2. Saudi Arabia
    • 10.2.3. Rest of MEA
  • 10.3. Market Size (US$ Mn) Forecast By Country, 2025 - 2032
    • 10.3.1. South Africa
    • 10.3.2. Saudi Arabia
    • 10.3.3. Rest of MEA
  • 10.4. Historical Market Size (US$ Mn) By Cancer Type, 2019 - 2024
    • 10.4.1. Uterine Sarcoma
    • 10.4.2. Endometrial Carcinomas
  • 10.5. Market Size (US$ Mn) Forecast By Cancer Type, 2025 - 2032
    • 10.5.1. Uterine Sarcoma
    • 10.5.2. Endometrial Carcinomas
  • 10.6. Historical Market Size (US$ Mn) By Test Type, 2019 - 2024
    • 10.6.1. Ultrasound Scanning
      • 10.6.1.1. Abdominal Ultrasound
      • 10.6.1.2. Transvaginal Ultrasound
    • 10.6.2. Biopsy
      • 10.6.2.1. Endometrial Biopsy
      • 10.6.2.2. Hysteroscopy
      • 10.6.2.3. Dilation and curettage
    • 10.6.3. Blood tests
      • 10.6.3.1. Complete blood Count
      • 10.6.3.2. CA-125 blood test
  • 10.7. Market Size (US$ Mn) Forecast By Test Type, 2025 - 2032
    • 10.7.1. Ultrasound Scanning
      • 10.7.1.1. Abdominal Ultrasound
      • 10.7.1.2. Transvaginal Ultrasound
    • 10.7.2. Biopsy
      • 10.7.2.1. Endometrial Biopsy
      • 10.7.2.2. Hysteroscopy
      • 10.7.2.3. Dilation and curettage
    • 10.7.3. Blood tests
      • 10.7.3.1. Complete blood Count
      • 10.7.3.2. CA-125 blood test
  • 10.8. Historical Market Size Analysis 2019 - 2024, By End User
    • 10.8.1. Hospitals
    • 10.8.2. Ambulatory Surgical Centers
    • 10.8.3. Cancer Research Centers
    • 10.8.4. Specialized Clinics
    • 10.8.5. Diagnostic Laboratories
    • 10.8.6. Others
  • 10.9. Market Size Analysis 2025 - 2032, By End User
    • 10.9.1. Hospitals
    • 10.9.2. Ambulatory Surgical Centers
    • 10.9.3. Cancer Research Centers
    • 10.9.4. Specialized Clinics
    • 10.9.5. Diagnostic Laboratories
    • 10.9.6. Others
  • 10.10. Drivers and Restraints: Impact Analysis
  • 10.11. Market Attractiveness Analysis
    • 10.11.1. By Cancer Type
    • 10.11.2. By Test Type
    • 10.11.3. By End user
    • 10.11.4. By Country

11. Forecast Factors: Relevance and Impact

12. Competition Landscape

  • 12.1. Competition Dashboard
  • 12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3. Key Players
    • 12.3.1. Abbott
    • 12.3.2. Roche Holdings AG
    • 12.3.3. Siemens AG
    • 12.3.4. Danaher
    • 12.3.5. BioMerieux SA

13. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Region

  • 13.1. Introduction
    • 13.1.1. Basis Point Share (BPS) Analysis by Region
    • 13.1.2. Y-o-Y Growth Projections by Region
  • 13.2. Historical Market Size Analysis 2019 - 2024, By Region
    • 13.2.1. North America
    • 13.2.2. Latin America
    • 13.2.3. Europe
    • 13.2.4. Asia Pacific Excluding China
    • 13.2.5. China
    • 13.2.6. Middle East and Africa (MEA)
  • 13.3. Market Size Analysis 2025 - 2032, By Region
    • 13.3.1. North America
    • 13.3.2. Latin America
    • 13.3.3. Europe
    • 13.3.4. Asia Pacific Excluding China
    • 13.3.5. China
    • 13.3.6. Middle East and Africa (MEA)
  • 13.4. Market Attractiveness Analysis by Region

14. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Cancer Type

  • 14.1. Introduction
    • 14.1.1. Basis Point Share (BPS) Analysis by Product Type
    • 14.1.2. Y-o-Y Growth Projections by Product Type
  • 14.2. Historical Market Size Analysis 2019 - 2024, By Cancer Type
    • 14.2.1. Uterine Sarcoma
    • 14.2.2. Endometrial Carcinomas
  • 14.3. Market Size Analysis 2025 - 2032, By Cancer Type
    • 14.3.1. Uterine Sarcoma
    • 14.3.2. Endometrial Carcinomas
  • 14.4. Market Attractiveness Analysis by Cancer Type

15. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By Diagnostic Test Type

  • 15.1. Introduction
    • 15.1.1. Basis Point Share (BPS) Analysis by Test Type
    • 15.1.2. Y-o-Y Growth Projections by Test Type
  • 15.2. Historical Market Size Analysis 2019 - 2024, By Test Type
    • 15.2.1. Ultrasound Scanning
      • 15.2.1.1. Abdominal Ultrasound
      • 15.2.1.2. Transvaginal Ultrasound
    • 15.2.2. Biopsy
      • 15.2.2.1. Endometrial Biopsy
      • 15.2.2.2. Hysteroscopy
      • 15.2.2.3. Dilation and curettage
    • 15.2.3. Blood tests
      • 15.2.3.1. Complete blood Count
      • 15.2.3.2. CA-125 blood test
  • 15.3. Market Size Analysis 2025 - 2032, By Test Type
    • 15.3.1. Ultrasound Scanning
      • 15.3.1.1. Abdominal Ultrasound
      • 15.3.1.2. Transvaginal Ultrasound
    • 15.3.2. Biopsy
      • 15.3.2.1. Endometrial Biopsy
      • 15.3.2.2. Hysteroscopy
      • 15.3.2.3. Dilation and curettage
    • 15.3.3. Blood tests
      • 15.3.3.1. Complete blood Count
      • 15.3.3.2. CA-125 blood test
  • 15.4. Market Attractiveness Analysis by Test Type

16. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032, By End User

  • 16.1. Introduction
    • 16.1.1. Basis Point Share (BPS) Analysis by End User
    • 16.1.2. Y-o-Y Growth Projections by End User
  • 16.2. Historical Market Size Analysis 2019 - 2024, By End User
    • 16.2.1. Hospitals
    • 16.2.2. Ambulatory Surgical Centers
    • 16.2.3. Cancer Research Centers
    • 16.2.4. Specialized Clinics
    • 16.2.5. Diagnostic Laboratories
    • 16.2.6. Others
  • 16.3. Market Size Analysis 2025 - 2032, By End User
    • 16.3.1. Hospitals
    • 16.3.2. Ambulatory Surgical Centers
    • 16.3.3. Cancer Research Centers
    • 16.3.4. Specialized Clinics
    • 16.3.5. Diagnostic Laboratories
    • 16.3.6. Others
  • 16.4. Market Attractiveness Analysis by End User

17. Global Uterine Cancer Diagnostic Testing Market Analysis 2019 - 2024 and Forecast 2025 - 2032

  • 17.1. Market Size and Y-o-Y Growth
  • 17.2. Absolute $ Opportunity

18. Assumptions and Acronyms Used

A glossary of assumption and acronyms used in the report

19. Research Methodology